Extended-Spectrum β-Lactamase-Producing Enterobacterales
DOI:
https://doi.org/10.14456/2022s10301Keywords:
Extended-spectrum β-lactamases-producing Enterobacterales, ESBL genes, Transmission , Risk factors, Prevalence and surveillanceAbstract
Extended-spectrum β-lactamases-producing Enterobacterales is one of the global health concern due to rapid global spread and threatening infections. It is known as “superbugs” causing both hospital-acquired and community-acquired infections. ESBLgenes dissemination is associated with mobile genetic elements on plasmid resulting in rapid transmission. Emerging of ESBL producers can occur by horizontal gene transfer. It is suggested that screening for ESBL colonization should be carried out in the high-risk groups. Moreover, appropriate antibiotic use for treatment is imperative to prevent development of bacterial resistance against new antibiotics. Global surveillance of extended-spectrum β-lactamase producing Escherichia coli is currently carried out with a tricycle protocol. It is crucial to encourage active surveillance and infection control to prevent ESBL genes transmission.
Downloads
References
World Health Organization. Antimicrobial resistance. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/
antimicrobial-resistance. Accessed April 9, 2022.
Centers for Disease Control and Prevention. Beta-Lactamase-Producing Enterobactericeae. In Antibiotic resistance threats in the United States, 2013. US Department of Health and Human Services Atlanta; 2013.
PitoutJD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56(1):52-59.
Brolund A. Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infect Ecol Epidemiol. 2014;4.
Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007;55(3):254-259.
Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14(4):933-951.
Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-686.
ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J. The Growing Genetic and Functional Diversity of Extended Spectrum BetaLactamases. BioMed Research International. 2018;2018:9519718.
Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17. J Antimicrob Chemother. 2020;75(5): 1165-1173.
Castanheira M, Simner PJ, Bradford PA. Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection. JAC-Antimicrobial Resistance. 2021;3(3).
Livermore DM, Paterson DL. Pocket guide to extended-spectrum β-lactamases in resistance. Current Medicine Group; 2006.
Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Entero-bacteriaceae: an emerging public-health concern. The Lancet infectious diseases. 2008;8(3):159-166.
Woerther PL, Angebault C, Jacquier H, et al. Characterization of fecal extendedspectrum-β-lactamase-producing Escherichia coli in a remote community during a long time period. Antimicrob Agents Chemother. 2013;57(10):5060-5066.
Vasaikar S, Obi L, Morobe I, Bisi-Johnson M. Molecular Characteristics and Antibiotic Resistance Profiles of Klebsiella Isolates in Mthatha, Eastern Cape Province, SouthAfrica. Int J Microbiol. 2017;2017:8486742.
Kluytmans-van den Bergh MF, Rossen JW, Bruijning-Verhagen PC, et al. Whole Genome Multilocus Sequence Typing of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae. J Clin Microbiol. 2016;54(12):2919-2927.
Falgenhauer L, Imirzalioglu C, Oppong K, et al. Detection and Characterization of ESBL-Producing Escherichia coli From Humans and Poultry in Ghana. Original Research. Front Microbiol. 2019;9.
Moghnieh R, Abdallah D, Jadayel M, et al. Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales. Sci Rep. 2021;11(1):14757.
Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995;8(4):557-584.
Pongpech P, Naenna P, Taipobsakul Y, Tribuddharat C, Srifuengfung S. Prevalence of extended-spectrum beta-lactamase and class 1 integron integrase gene intl1 in Escherichia coli from Thai patients and healthy adults. Southeast Asian J Trop Med Public Health. 2008;39(3):425-433.
Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6(9):460-463.
BellJM, Turnidge JD,Jones RN. Prevalence of extended-spectrum beta-lactamase-producing Enterobacter cloacae in the Asia-Pacific
region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001. Antimicrob Agents Chemother. 2003;47(12):3989-
Kader AA, Kumar A. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Ann Saudi Med. 2005;25(3):239-242.
Ryoo NH, Kim EC, Hong SG, et al. Dissemination of SHV-12 and CTX-M-type extended-spectrum beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Antimicrob Chemother. 2005;56(4):
-702.
Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis. 2005;52(4):323-329.
Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579-587.
Luvsansharav UO, Hirai I, Niki M, et al. Analysis of risk factors for a high prevalence of extended-spectrum b-lactamase-producing Enterobacteriaceae in asymptomatic individuals in rural Thailand. J Med Microbiol. 2011;60(5):619-624.
Adler A, Baraniak A, Izdebski R, et al. A multinational study of colonization with extended spectrum β-lactamase-producing Enterobacteriaceae in healthcare personnel and family members of carrier patients hospitalized in rehabilitation centres. Clinical Microbiology and Infection. 2014;20(8):516-523.
van Prehn J, KaiserAM, van der Werff SD, van Mansfeld R, Vandenbroucke-Grauls C. Colonization sites in carriers of ESBL-producing Gram-negative bacteria. Antimicrob Resist Infect Control. 2018;7:52.
Papst L, Beović B, Seme K, Pirš M. Two-year prospective evaluation of colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae: time course and risk factors. Infect Dis (Lond). 2015;47(9):618-624.
Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF. Sites of colonization with extended-spectrum β-lactamases (ESBL)-producing enterobacteriaceae: the rationale for screening. Infect Control Hosp Epidemiol. 2012;33(11):1170-1171.
Rodriguez-Bano J, Pascual A. Clinical significance of extended-spectrum β-lactamases. Expert Review of Anti-infective Therapy.
;6(5):671-683.
Turbett SE, Mansour MK. Editorial Commentary: Fecal ESBL Screening: Are We Ready for This Information? Clin Infect Dis. 2016;
(3):319-321.
Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. Clin Infect Dis. 2016;63(3):310-318.
Cornejo-Juarez P, Suarez-Cuenca JA, VolkowFernandez P, et al. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia
in patients with hematological malignancies. Support Care Cancer. 2016;24(1):253-259.
Apisarnthanarak A, Kondo S, Mingmalairak C, et al. Outcomes of extended-spectrum beta-lactamases producing Enterobacteriaceae colonization among patients abdominal surgery patients. Infect Control Hosp Epidemiol. 2019;40(11):1290-1293.
Nutman A, Carmeli Y. Reply to Apisarnthanarak and Apisarnthanarak. Clin Infect Dis. 2020;71(8):2025.
Nutman A, Temkin E, Harbarth S, et al. Personalized Ertapenem Prophylaxis for Carriers of Extended-spectrum β-Lactamase-producing Enterobacteriaceae Undergoing Colorectal Surgery. Clin Infect Dis. 2020;70(9):1891-1897.
Apisarnthanarak A, Kondo S, Apisarnthanarak P, Mundy LM. Risk factorsfor extended-spectrum beta-lactamase-producing Enterobacteriaceae enteric carriage among abdominal surgery patients. Infect Control Hosp Epidemiol. 2020;41(9):1098-1100.
World Health Organization. WHO integrated global surveillance on ESBL-producing E. coli using a “One Health” approach: implementation and opportunities. World Health Organization. https://www.who.int/publications/i/item/who-integrated-global-surveillance on-esbl-producing-e.-coli-using-a-one-healthapproach. Published March 16, 2021. Accessed 2022.
Adam HJ, Louie L, Watt C, et al. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus
aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob Agents
Chemother. 2010;54(2):945-949.
Peirano G, Pitout JDD. Extended-Spectrum β-Lactamase-Producing Enterobac-teriaceae: Update on Molecular Epidemiology and
Treatment Options. Drugs. 2019;79(14):1529-1541.
Troche G, Joly LM, Guibert M, Zazzo JF. Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care
unit: a 6-year prospective survey. Infect Control Hosp Epidemiol. 2005;26(2):161-165.
Gardam MA, Burrows LL, Kus JV, et al. Is surveillance for multidrug-resistant enterobacteriaceae an effective infection controlstrategy in the absence of an outbreak? J Infect Dis. 2002;186(12):1754-1760.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Asian Medical Journal and Alternative Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
